Virchow Biotech Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Virchow Biotech Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Virchow Biotech Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.3M Trade | TransData Nexus

Virchow Biotech Private Limited

Indian Pharmaceutical Exporter · Other Specialist · $1.3M Total Trade · DGFT Verified

Virchow Biotech Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.3M across 2 products in 2 therapeutic categories. Based on 25 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Immunoglobulin ($1.0M), Syringe ($250.0K), .

Virchow Biotech Private Limited — Export Portfolio & Destination Treemap

Virchow Biotech Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Virchow Biotech Private Limited? — Company Overview & Market Position

Virchow Biotech Private Limited (VBPL) is a prominent biopharmaceutical company headquartered in Hyderabad, India. Established on April 4, 2001, the company specializes in the development and manufacturing of high-quality biogenerics, pharmaceuticals, medical devices, and active pharmaceutical ingredients (APIs). As part of the Virchow Group, VBPL leverages over four decades of operational experience, with the group serving over 100 countries and employing approximately 3,500 professionals.

The company is registered under the Corporate Identification Number (CIN) U24210TG2001PTC036520. Its authorized capital stands at ₹205 million, with a paid-up capital of ₹170.33 million. As of April 7, 2024, VBPL employs approximately 1,048 individuals. The company's official website is virchowbiotech.com.

What Does Virchow Biotech Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Immunoglobulin$1.0M 2Syringe

Product Portfolio — Top 2 by Export Value

Virchow Biotech Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Immunoglobulin	Other	$1.0M	20	0.6%	9
2	Syringe	Medical Devices & Diagnostics	$250.0K	5	0.1%	13

Virchow Biotech Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.3M. The top category is Other (80.0% of portfolio), followed by Medical Devices & Diagnostics (20.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Virchow Biotech Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

VBPL operates state-of-the-art manufacturing facilities in Hyderabad, India, adhering to stringent quality standards. The facilities are certified by the World Health Organization's Good Manufacturing Practices (WHO-GMP) and ISO 13485:2016, ensuring compliance with international quality benchmarks. These facilities are equipped with advanced clean-room environments and fill-finish lines, enabling the production of a diverse range of pharmaceutical products, including biogenerics, recombinant proteins, and medical devices.

3Key Leadership

The leadership team at VBPL is spearheaded by Managing Director Hemanth Nandigala, who has been instrumental in the company's growth and strategic direction. The board of directors includes Narayana Reddy Mundla, Venkata Reddy Nandigala, and Murali Krishna Reddy Tummuru. While specific details about the Chief Financial Officer (CFO) and other key executives are not publicly disclosed, the company's leadership is known for its commitment to innovation and quality in the biopharmaceutical sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Virchow Biotech Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

VBPL has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds approvals from the U.S. Food and Drug Administration (FDA) and the World Health Organization's Good Manufacturing Practices (WHO-GMP), facilitating access to these markets. Additionally, VBPL has received approvals from regulatory bodies in Brazil (ANVISA GMP), Colombia (INVIMA GMP), and Canada (NNHPD), further expanding its global footprint.

2Emerging Markets

VBPL has made strategic inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enhances its ability to meet international quality standards, facilitating market access in these regions. By obtaining approvals from regulatory authorities in countries such as Brazil, Colombia, and Canada, VBPL demonstrates its commitment to expanding its global reach and serving diverse patient populations.

3Geographic Strategy

VBPL's geographic strategy reflects a balanced approach to market diversification and risk management. The company's presence in both developed and emerging markets allows it to leverage growth opportunities while mitigating potential risks associated with over-reliance on a single region. By obtaining approvals from various international regulatory bodies, VBPL demonstrates its commitment to meeting global quality standards and expanding its global footprint.

Virchow Biotech Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

VBPL's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), indicating compliance with U.S. regulatory standards. The company has received FDA approvals for its products, facilitating market access in the United States. Specific details regarding approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the FDA registration and approvals underscore VBPL's commitment to maintaining high-quality manufacturing practices.

2WHO & EU GMP

VBPL holds certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and the European Union's Good Manufacturing Practices (EU GMP), demonstrating compliance with international quality standards. These certifications are crucial for market access in various countries and reflect the company's dedication to producing high-quality pharmaceutical products.

3CDSCO & Indian Regulatory

Virchow Biotech Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the biopharmaceutical sector, VBPL faces competition from both domestic and international companies offering similar products. While specific market share data is not publicly disclosed, VBPL's certifications from WHO-GMP, EU GMP, and FDA, along with its diverse product portfolio, position it as a competitive player in the global market.

2Key Differentiators

VBPL's key differentiators include its extensive experience in biopharmaceuticals, commitment to innovation, and adherence to international quality standards. The company's specialization in biogenerics, recombinant proteins, and medical devices, coupled with its global certifications, underscores its competitive advantages in the industry.

3Strategic Position

VBPL's strategic direction focuses on the development and commercialization of biogenerics, recombinant proteins, and medical devices. The company's adherence to international quality standards and its global certifications position it well for future growth and expansion in the biopharmaceutical sector.

Buyer Due Diligence Brief — Evaluating Virchow Biotech Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

VBPL has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's adherence to international quality standards, as evidenced by its certifications from WHO-GMP, EU GMP, and FDA, indicates reliability and commitment to quality.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm the company's registration and product approvals with the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure the company holds certification from the World Health Organization's Good Manufacturing Practices.

EU GMP Certification: Verify the company's compliance with the European Union's Good Manufacturing Practices.

Frequently Asked Questions — Virchow Biotech Private Limited

How many pharmaceutical products does Virchow Biotech Private Limited export from India?

Virchow Biotech Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Immunoglobulin ($1.0M), Syringe ($250.0K). Total export value is $1.3M.

What is Virchow Biotech Private Limited's total pharmaceutical export value?

Virchow Biotech Private Limited's total pharmaceutical export value is $1.3M, based on 25 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Virchow Biotech Private Limited cover?

Virchow Biotech Private Limited exports across 2 therapeutic categories. The largest are Other (80.0%, 1 products), Medical Devices & Diagnostics (20.0%, 1 products).

Get Full Virchow Biotech Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.